CANTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30th, 2023.
Third Quarter 2023 Financial Results Summary:
"Our third quarter revenue results were impacted by the LCD-related issues discussed on our second quarter call," said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. “Notably, despite the revenue impact, we delivered significant improvements in our operating profitability and generated strong adjusted EBITDA and cash flow compared to the prior year period.”
Mr. Gillheeney, Sr. continued: “While we are pleased that the LCDs were withdrawn, we continue to navigate through the challenging environment created by their proposed adoption. We have reintroduced our 2023 financial guidance which reflects the impacts of business disruption in the third quarter, as well as our recovery activities throughout the end of the year. We expect to continue to build momentum as we close out 2023 and remain confident that we are well positioned for growth with our broad portfolio of products across all sites of care as we deliver on our mission to provide integrated healing solutions that substantially improve outcomes while lowering the overall cost of care.”
1Defined as GAAP net income (loss) adjusted to exclude the effect of amortization, restructuring charges, LCD legal fees and sales retention, write off of certain assets, facility construction project pause costs, GPO settlement fee and the resulting income taxes on these items.
Third Quarter 2023 Financial Results:
| Three Months Ended September 30, | Change | ||||||||||||||
| 2023 | 2022 | $ | % | ||||||||||||
| (in thousands, except for percentages) | |||||||||||||||
| Advanced Wound Care | $ | 101,357 | $ | 109,514 | $ | (8,157 | ) | (7%) | |||||||
| Surgical & Sports Medicine | 7,174 | 7,345 | (171 | ) | (2%) | ||||||||||
| Net revenue | $ | 108,531 | $ | 116,859 | $ | (8,328 | ) | (7%) | |||||||
Net revenue for the third quarter of 2023 was $108.5 million, compared to $116.9 million for the third quarter of 2022, a decrease of $8.3 million, or 7%. The decrease in net revenue was driven by a decrease of $8.2 million, or 7% in net revenue for Advanced Wound Care products and a decrease of $0.2 million, or 2%, in net revenue for Surgical & Sports Medicine products.
Gross profit for the third quarter of 2023 was $82.7 million, or 76% of net revenue, compared to $90.7 million, or 78% of net revenue for the third quarter of 2022, a decrease of $7.9 million, or 9%.
Operating expenses for the third quarter of 2023 were $74.7 million compared to $88.9 million for the third quarter of 2022, a decrease of $14.2 million, or 16%. R&D expense was $10.5 million for the third quarter of 2023, compared to $9.6 million for the third quarter of 2022, an increase of $0.9 million, or 9%. Selling, general and administrative expenses were $64.2 million for the third quarter of 2023, compared to $79.3 million for the third quarter of 2022, a decrease of $15.1 million, or 19%.
Operating income for the third quarter of 2023 was $8.1 million, compared to operating income of $1.8 million for the third quarter of 2022, an increase of $6.3 million, or 352%.
Total other expense, net, for the third quarter of 2023 was $0.4 million, compared to $0.6 million for the third quarter of 2022, a decrease of $0.2 million, or 27%.
Net income for the third quarter of 2023 was $3.2 million, or $0.02 per share, compared to net income of $0.2 million, or $0.00 per share, for the third quarter of 2022, an increase of $3.0 million, or $0.02 per share.
Adjusted net income of $5.3 million for the third quarter of 2023, compared to adjusted net income of $5.1 million for the third quarter of 2022, an increase of $0.2 million, or 4%.
Adjusted EBITDA was $16.0 million for the third quarter of 2023, compared to $11.6 million for the third quarter of 2022, an increase of $4.4 million, or 38%.
As of September 30th, 2023, the Company had $98.8 million in cash, cash equivalents and restricted cash and $67.6 million in debt obligations, compared to $103.3 million in cash, cash equivalents and restricted cash and $70.8 million in debt obligations as of December 31, 2022.
Nine Months ended September 30, 2023, Results
The following table represents net revenue by product grouping for the nine months ended September 30, 2023 and September 30, 2022, respectively:
| Nine Months Ended September 30, | Change | ||||||||||||||
| 2023 | 2022 | $ | % | ||||||||||||
| (in thousands, except for percentages) | |||||||||||||||
| Advanced Wound Care | $ | 312,349 | $ | 313,395 | $ | (1,046 | ) | 0% | |||||||
| Surgical & Sports Medicine | 21,140 | 21,982 | (842 | ) | (4%) | ||||||||||
| Net revenue | $ | 333,489 | $ | 335,377 | $ | (1,888 | ) | (1%) | |||||||
Net revenue for the nine months ended September 30, 2023 was $333.5 million, compared to $335.4 million for the nine months ended September 30, 2022, a decrease of $1.9 million, or 1%. The decrease in net revenue was driven by a decrease of $1.0 million, or less than 1%, in net revenue for Advanced Wound Care products and by a decrease of $0.8 million, or 4% in net revenue for Surgical & Sports Medicine products.
Gross profit for the nine months ended September 30, 2023 was $254.8 million, or 76% of net revenue, compared to $257.5 million, or 77% of net revenue, for the nine months ended September 30, 2022, a decrease of $2.7 million, or 1%.
Operating expenses for the nine months ended September 30, 2023 were $241.0 million, compared to $243.9 million for the nine months September 30, 2022, a decrease of $2.9 million, or 1%. R&D expense was $32.6 million for the nine months ended September 30, 2023, compared to $28.4 million in the nine months ended September 30, 2022, an increase of $4.2 million, or 15%. Selling, general and administrative expenses were $208.4 million for the nine months ended September 30, 2023, compared to $215.5 million in the nine months ended September 30, 2022, a decrease of $7.1 million, or 3%.
Operating income for the nine months ended September 30, 2023 was $13.8 million, compared to operating income of $13.6 million for the nine months ended September 30, 2022, an increase of $0.2 million, or 2%.
Total other expenses, net, for the nine months ended September 30, 2023 were $1.6 million, compared to $2.1 million for the nine months ended September 30, 2022, a decrease of $0.5 million, or 22%.
Net income of $5.5 million for the nine months ended September 30, 2023 or $0.04 per share, compared to net income of $8.0 million, or $0.06 per share for the nine months ended September 30, 2022, a decrease of $2.5 million, or $0.02, per share.
Adjusted net income for the nine months ended September 30, 2023 was $10.7 million compared to $17.3 million, for the nine months ended September 30, 2022, a decrease of $6.5 million, or 38%.
Adjusted EBITDA of $35.1 million for the nine months ended September 30, 2023, compared to an Adjusted EBITDA of $35.2 million, for the nine months ended September 30, 2022, a decrease of $0.1 million, or less than 1%.
Fiscal Year 2023 Guidance:
For the year ending December 31, 2023, the Company expects:
Third Quarter Earnings Conference Call:
Financial results for the third fiscal quarter of 2023 will be reported after the market closes on November, 9th. Management will host a conference call at 5:00 p.m. Eastern Time on November 9th to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.organogenesis.com. The webcast will be archived on the company website for one year.
ORGANOGENESIS HOLDINGS INC.
UNAUDITED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except share and per share data)
| September 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 98,226 | $ | 102,478 | ||||
| Restricted cash | 599 | 812 | ||||||
| Accounts receivable, net | 89,276 | 89,450 | ||||||
| Inventory, net | 27,905 | 24,783 | ||||||
| Prepaid expenses and other current assets | 9,567 | 5,086 | ||||||
| Total current assets | 225,573 | 222,609 | ||||||
| Property and equipment, net | 117,503 | 102,463 | ||||||
| Intangible assets, net | 17,101 | 20,789 | ||||||
| Goodwill | 28,772 | 28,772 | ||||||
| Operating lease right-of-use assets, net | 42,363 | 43,192 | ||||||
| Deferred tax asset, net | 30,014 | 30,014 | ||||||
| Other assets | 1,321 | 1,520 | ||||||
| Total assets | $ | 462,647 | $ | 449,359 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Current portion of term loan, net of debt issuance costs | $ | 5,483 | $ | 4,538 | ||||
| Current portion of finance lease obligations | 1,174 | - | ||||||
| Current portion of operating lease obligations | 13,048 | 11,708 | ||||||
| Accounts payable | 26,784 | 32,330 | ||||||
| Accrued expenses and other current liabilities | 34,993 | 26,447 | ||||||
| Total current liabilities | 81,482 | 75,023 | ||||||
| Term loan, net of current portion and debt issuance costs | 62,117 | 66,231 | ||||||
| Finance lease obligations, net of current portion | 2,166 | - | ||||||
| Operating lease obligations, net of current portion | 38,826 | 41,314 | ||||||
| Other liabilities | 1,191 | 1,122 | ||||||
| Total liabilities | 185,782 | 183,690 | ||||||
| Commitments and contingencies (Note 18) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued | - | - | ||||||
| Common stock, $0.0001 par value; 400,000,000 shares authorized; 132,041,164 and 131,647,677 shares issued; 131,312,616 and 130,919,129 shares outstanding at September 30, 2023 and December 31, 2022, respectively. | 13 | 13 | ||||||
| Additional paid-in capital | 317,254 | 310,957 | ||||||
| Accumulated deficit | (40,402 | ) | (45,301 | ) | ||||
| Total stockholders’ equity | 276,865 | 265,669 | ||||||
| Total liabilities and stockholders’ equity | $ | 462,647 | $ | 449,359 | ||||
ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
(amounts in thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net revenue | $ | 108,531 | $ | 116,859 | $ | 333,489 | $ | 335,377 | ||||||||
| Cost of goods sold | 25,789 | 26,177 | 78,712 | 77,909 | ||||||||||||
| Gross profit | 82,742 | 90,682 | 254,777 | 257,468 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 64,222 | 79,328 | 208,373 | 215,515 | ||||||||||||
| Research and development | 10,470 | 9,575 | 32,610 | 28,367 | ||||||||||||
| Total operating expenses | 74,692 | 88,903 | 240,983 | 243,882 | ||||||||||||
| Income from operations | 8,050 | 1,779 | 13,794 | 13,586 | ||||||||||||
| Other expense, net: | ||||||||||||||||
| Interest expense, net | (444 | ) | (572 | ) | (1,688 | ) | (2,039 | ) | ||||||||
| Other income (expense), net | 31 | 5 | 82 | (19 | ) | |||||||||||
| Total other expense, net | (413 | ) | (567 | ) | (1,606 | ) | (2,058 | ) | ||||||||
| Net income before income taxes | 7,637 | 1,212 | 12,188 | 11,528 | ||||||||||||
| Income tax expense | (4,470 | ) | (997 | ) | (6,675 | ) | (3,482 | ) | ||||||||
| Net income | $ | 3,167 | $ | 215 | $ | 5,513 | $ | 8,046 | ||||||||
| Net income, per share: | ||||||||||||||||
| Basic | $ | 0.02 | $ | 0.00 | $ | 0.04 | $ | 0.06 | ||||||||
| Diluted | $ | 0.02 | $ | 0.00 | $ | 0.04 | $ | 0.06 | ||||||||
| Weighted-average common shares outstanding | ||||||||||||||||
| Basic | 131,312,483 | 130,903,160 | 131,230,882 | 129,784,890 | ||||||||||||
| Diluted | 133,417,721 | 132,232,954 | 132,790,296 | 132,555,265 | ||||||||||||
ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS
(amounts in thousands, except share and per share data)
| Nine Months Ended September 30, | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities: | ||||||||
| Net Income | $ | 5,513 | $ | 8,046 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation | 7,466 | 4,331 | ||||||
| Amortization of intangible assets | 3,689 | 3,662 | ||||||
| Reduction in the carrying value of right-of-use assets | 5,964 | 5,483 | ||||||
| Non-cash interest expense | 321 | 326 | ||||||
| Deferred interest expense | 367 | 428 | ||||||
| Provision recorded for credit losses | 1,320 | 855 | ||||||
| Loss on disposal of property and equipment | 104 | 4,412 | ||||||
| Adjustment for excess and obsolete inventories | 4,351 | 7,621 | ||||||
| Stock-based compensation | 6,630 | 4,697 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (1,761 | ) | (11,510 | ) | ||||
| Inventory | (7,473 | ) | (7,282 | ) | ||||
| Prepaid expenses and other current assets | (4,491 | ) | 1 | |||||
| Operating leases | (6,282 | ) | (5,250 | ) | ||||
| Accounts payable | (3,661 | ) | 5,261 | |||||
| Accrued expenses and other current liabilities | 8,179 | (4,061 | ) | |||||
| Other liabilities | 68 | 39 | ||||||
| Net cash provided by operating activities | 20,304 | 17,059 | ||||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (21,040 | ) | (23,242 | ) | ||||
| Net cash used in investing activities | (21,040 | ) | (23,242 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Payments of term loan under the 2021 Credit Agreement | (3,281 | ) | (938 | ) | ||||
| Payments of withholding taxes in connection with RSUs vesting | (333 | ) | (648 | ) | ||||
| Proceeds from the exercise of stock options | - | 2,070 | ||||||
| Principal repayments of finance lease obligations | (114 | ) | (200 | ) | ||||
| Payment of deferred acquisition consideration | - | (608 | ) | |||||
| Net cash used in financing activities | (3,728 | ) | (324 | ) | ||||
| Change in cash, cash equivalents and restricted cash | (4,465 | ) | (6,507 | ) | ||||
| Cash, cash equivalents, and restricted cash, beginning of period | 103,290 | 114,528 | ||||||
| Cash, cash equivalents, and restricted cash, end of period | $ | 98,825 | $ | 108,021 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | 3,896 | $ | 1,787 | ||||
| Cash paid for income taxes | $ | 3,021 | $ | 974 | ||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Purchases of property and equipment included in accounts payable and accrued expenses | $ | 4,146 | $ | 5,547 | ||||
| Right-of-use assets obtained through lease obligations | $ | 5,138 | $ | 1,708 | ||||
| Shares issued for deferred acquisition consideration | $ | - | $ | 828 | ||||
Non-GAAP Financial Measures
Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA and adjusted net income to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA and adjusted net income help identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA and adjusted net income provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.
The following table presents a reconciliation of GAAP net income to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for the periods presented:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) (in thousands) | ||||||||||||||||
| Net Income | $ | 3,167 | $ | 215 | $ | 5,513 | $ | 8,046 | ||||||||
| Interest expense, net | 444 | 572 | 1,688 | 2,039 | ||||||||||||
| Income tax expense | 4,470 | 997 | 6,675 | 3,482 | ||||||||||||
| Depreciation | 2,544 | 1,456 | 7,466 | 4,331 | ||||||||||||
| Amortization | 1,229 | 1,220 | 3,689 | 3,662 | ||||||||||||
| EBITDA | 11,854 | 4,460 | 25,031 | 21,560 | ||||||||||||
| Stock-based compensation expense | 2,417 | 1,702 | 6,630 | 4,697 | ||||||||||||
| Restructuring charge (1) | 95 | 611 | 1,878 | 1,518 | ||||||||||||
| Legal fees (2) | 1,182 | - | 1,182 | - | ||||||||||||
| Sales retention (3) | 422 | - | 422 | - | ||||||||||||
| Write-off of certain assets (4) | - | 4,200 | - | 4,200 | ||||||||||||
| Facility construction project pause (5) | - | 632 | - | 632 | ||||||||||||
| Settlement fee (6) | - | - | - | 2,600 | ||||||||||||
| Adjusted EBITDA | $ | 15,970 | $ | 11,605 | $ | 35,143 | $ | 35,207 | ||||||||
The following table presents a reconciliation of GAAP net income to non-GAAP adjusted net income, for the periods presented:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) (in thousands) | (in thousands) | |||||||||||||||
| Net Income | $ | 3,167 | $ | 215 | $ | 5,513 | $ | 8,046 | ||||||||
| Amortization | 1,229 | 1,220 | 3,689 | 3,662 | ||||||||||||
| Restructuring charge (1) | 95 | 611 | 1,878 | 1,518 | ||||||||||||
| Legal fees (2) | 1,182 | - | 1,182 | - | ||||||||||||
| Sales retention (3) | 422 | - | 422 | - | ||||||||||||
| Write-off of certain assets (4) | - | 4,200 | - | 4,200 | ||||||||||||
| Facility construction project pause (5) | - | 632 | - | 632 | ||||||||||||
| Settlement fee (6) | - | - | - | 2,600 | ||||||||||||
| Tax on above | (791 | ) | (1,781 | ) | (1,936 | ) | (3,371 | ) | ||||||||
| Adjusted net income | $ | 5,304 | $ | 5,097 | $ | 10,748 | $ | 17,287 | ||||||||
The following table presents a reconciliation of projected GAAP net income to projected non-GAAP EBITDA and projected non-GAAP Adjusted EBITDA included in our guidance for the year ending December 31, 2023:
| Year Ending December 31, | ||||||||
| 2023L | 2023H | |||||||
| Net income | $ | 4,200 | $ | 9,300 | ||||
| Interest expense | 2,700 | 2,700 | ||||||
| Income tax expense | 4,700 | 9,700 | ||||||
| Depreciation | 9,900 | 9,900 | ||||||
| Amortization | 4,900 | 4,900 | ||||||
| EBITDA | $ | 26,400 | $ | 36,500 | ||||
| Stock-based compensation expense | 9,000 | 9,000 | ||||||
| Restructuring charge | 3,400 | 3,400 | ||||||
| LCD legal fees and sales retention | 1,600 | 1,600 | ||||||
| Adjusted EBITDA | $ | 40,400 | $ | 50,500 | ||||
The following table presents a reconciliation of projected GAAP net income to projected non-GAAP adjusted net income included in our guidance for the year ending December 31, 2023:
| Year Ending December 31, | ||||||||
| 2023L | 2023H | |||||||
| Net income | $ | 4,200 | $ | 9,300 | ||||
| Amortization | 4,900 | 4,900 | ||||||
| Restructuring charge | 3,400 | 3,400 | ||||||
| LCD legal fees and sales retention | 1,600 | 1,600 | ||||||
| Tax on above | (2,700 | ) | (2,700 | ) | ||||
| Adjusted net income | $ | 11,400 | $ | 16,500 | ||||
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company’s expected revenue, net income, adjusted net income, EBITDA, and Adjusted EBITDA for fiscal 2023 and the breakdown of expected revenue in both its Advanced Wound Care and Surgical & Sports Medicine categories. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the coverage and reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company may owe rebates to the federal government prospectively on certain of its products if more than a certain percentage of the product is not administered to a patient and is discarded (wasted) by providers; (6) the Company’s ability to raise funds to expand its business; (7) the Company has incurred losses in prior years and may incur losses in the future; (8) changes in applicable laws or regulations; (9) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (10) the Company’s ability to maintain production of Affinity in sufficient quantities to meet demand; (11) any resurgence of the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; (12) the impact of the suspension of commercialization of: (a) ReNu and NuCel in connection with the expiration of the FDA’s enforcement grace period for HCT/Ps on May 31, 2021 and (b) Dermagraft in the second quarter of 2022 pending transition of manufacturing to a new manufacturing facility or a third-party manufacturer; and (13) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2022 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
| Last Trade: | US$4.05 |
| Daily Change: | 0.03 0.75 |
| Daily Volume: | 836,796 |
| Market Cap: | US$536.910M |
November 22, 2024 November 12, 2024 November 12, 2024 November 11, 2024 October 01, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
